(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https://doi.org/10.1101/2020.06.22.20133413 This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital… Continue reading "(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC"